Our Pipeline

Small molecules. Validated targets. Clear paths to patients.

KeifeRx is building a leading precision medicine pipeline for the treatment of neurodegenerative diseases including Alzheimer’s disease, Lewy body dementia, and Parkinson’s disease dementia, guided by deep biological understanding of disease progression.

Our robust pipeline of drug candidates is designed for superior brain penetration and efficacy, inhibiting validated kinase targets that address multiple components of neurodegenerative diseases, representing a potential new generation of therapies for patients with limited treatment options.

Development programs

KFRX01

Lead asset

Nilotinib Transdermal

Lewy Body Diseases

  1. 01Lead Op.
  2. 02IND-enabling
  3. 03Phase 1/2
  4. 04Late Stage

Validated TargetsDDR-1

StatusReady for Phase 2b/3 Trial

KFRX03

Alzheimer's Disease

  1. 01Lead Op.
  2. 02IND-enabling
  3. 03Phase 1/2
  4. 04Late Stage

Validated Targetsc-ABL, c-KIT, DDR-1

StatusPending Funding

KFRX06

Parkinson's DiseaseFrontotemporal Dementia

  1. 01Lead Op.
  2. 02IND-enabling
  3. 03Phase 1/2
  4. 04Late Stage

Validated TargetsLRRK2, c-ABL, c-KIT

Status Partnership

Co-development Opportunities

KFRX04

ALS

  1. 01Lead Op.
  2. 02IND-enabling
  3. 03Phase 1/2
  4. 04Late Stage

Validated Targetsc-KIT, PIKfyve

KFRX05

Neurodegeneration

  1. 01Lead Op.
  2. 02IND-enabling
  3. 03Phase 1/2
  4. 04Late Stage

Validated Targetsc-ABL, c-KIT (mutants)